Vascular inflammation and endothelial dysfunction in experimental hypertension

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Savoia, Carmine ^a   Sada, Lidia ^a   Zezza, Luigi ^a   Pucci, Lorenzo ^a   Lauri, Francesco Maria ^a   Befani, Alberto ^a   Alonzo, Alessandro ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; RENIN INHIBITOR;

ATHEROSCLEROSIS; BLOOD FLOW; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; EXPERIMENTAL STUDY; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR RESISTANCE; VASCULITIS; VASODILATATION;

EID: 84868270815     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/281240     Document Type: Review

References (96)

1. Schiffrin E. L., Reactivity of small blood vessels in hypertension: relation with structural changes: state of the art lecture. Hypertension 1992 19 2, supplement II1 II9 2-s2.0-0026600669
2. Schiffrin E. L., Resistance arteries as endpoints in hypertension. Blood Pressure, Supplement 1997 6 2, supplement S24 S30 2-s2.0-0031304321
3. Vanhoutte P. M., Shimokawa H., Tang E. H. C., Feletou M., Endothelial dysfunction and vascular disease. Acta Physiologica 2009 196 2 193 222 2-s2.0-65449160912 10.1111/j.1748-1716.2009.01964.x
4. Urbich C., Dimmeler S., Endothelial progenitor cells: characterization and role in vascular biology. Circulation Research 2004 95 4 343 353 2-s2.0-4143052506 10.1161/01.RES.0000137877.89448.78 (Pubitemid 39100452)
5. Hill J. M., Zalos G., Halcox J. P. J., Schenke W. H., Waclawiw M. A., Quyyumi A. A., Finkel T., Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. The New England Journal of Medicine 2003 348 7 593 600 2-s2.0-0037434561 10.1056/NEJMoa022287 (Pubitemid 36204953)
6. Durier S., Fassot C., Laurent S., Boutouyrie P., Couetil J. P., Fine E., Lacolley P., Dzau V. J., Pratt R. E., Physiological genomics of human arteries: quantitative relationship between gene expression and arterial stiffness. Circulation 2003 108 15 1845 1851 2-s2.0-0142085746 10.1161/01.CIR.0000091407. 86925.7A (Pubitemid 37296094)
7. Yu Y., Fukuda N., Yao E. H., Matsumoto T., Kobayashi N., Suzuki R., Tahira Y., Ueno T., Matsumoto K., Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. American Journal of Hypertension 2008 21 1 72 77 2-s2.0-38349129600 10.1038/ajh.2007.5
8. Ross R., Atherosclerosis-an inflammatory disease. The New England Journal of Medicine 1999 340 115 126
9. Lerman A., Zeiher A. M., Endothelial function: cardiac events. Circulation 2005 111 3 363 368 2-s2.0-12844253061 10.1161/01.CIR.0000153339. 27064.14 (Pubitemid 40165345)
10. Endemann D. H., Schiffrin E. L., Endothelial dysfunction. Journal of the American Society of Nephrology 2004 15 8 1983 1992 2-s2.0-3543133645 10.1097/01.ASN.0000132474.50966.DA (Pubitemid 39031337)
11. Savoia C., Schiffrin E. L., Inflammation in hypertension. Current Opinion in Nephrology and Hypertension 2006 15 2 152 158 2-s2.0-33646789812 10.1097/01.mnh.0000203189.57513.76
12. Savoia C., Schiffrin E. L., Inhibition of the renin angiotensin system: implications for the endothelium. Current Diabetes Reports 2006 6 4 274 278 2-s2.0-33748325643 10.1007/s11892-006-0060-5 (Pubitemid 44322699)
13. Kranzhöfer R., rogerkranzhoefer@med.uni-heidelberg.de Schmidt J., Pfeiffer C. A. H., Hagl S., Libby P., Kübler W., Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 7 1623 1629 (Pubitemid 29323820)
14. De Ciuceis C., Amiri F., Brassard P., Endemann D. H., Touyz R. M., Schiffrin E. L., Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 10 2106 2113 2-s2.0-26244446955 10.1161/01.ATV.0000181743. 28028.57 (Pubitemid 41416308)
15. Savoia C., Schiffrin E. L., Reduction of C-reactive protein and the use of anti-hypertensives. Vascular Health and Risk Management 2007 3 6 975 983 2-s2.0-38149098447
16. Blake G. J., Ridker P. M., Novel clinical markers of vascular wall inflammation. Circulation Research 2001 89 9 763 771 2-s2.0-0035955760 (Pubitemid 34633846)
17. Sesso H. D., Buring J. E., Rifai N., Blake G. J., Gaziano J. M., Ridker P. M., C-reactive protein and the risk of developing hypertension. Journal of the American Medical Association 2003 290 22 2945 2951 2-s2.0-0345492466 10.1001/jama.290.22.2945 (Pubitemid 37505526)
18. Preston R. A., Ledford M., Materson B. J., Baltodano N. M., Memon A., Alonso A., Effects of severe, uncontrolled hypertension on endothelial activation: soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand Factor. Journal of Hypertension 2002 20 5 871 877 2-s2.0-0036562970 10.1097/00004872-200205000-00021 (Pubitemid 34913667)
19. Blake G. J., Rifai N., Buring J. E., Ridker P. M., Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003 108 24 2993 2999 2-s2.0-0347625841 10.1161/01.CIR.0000104566.10178.AF (Pubitemid 37553568)
20. Thorand B., Löwel H., Schneider A., Kolb H., Meisinger C., Fröhlich M., Koenig W., C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg Cohort Study, 19841998. Archives of Internal Medicine 2003 163 1 93 99 2-s2.0-0037434058 10.1001/archinte.163.1.93 (Pubitemid 36091606)
21. Libby P., Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001 104 3 365 372 2-s2.0-0035902456 (Pubitemid 32666962)
22. Schiffrin E. L., Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. American Journal of Hypertension 2004 17 12 1192 1200 2-s2.0-11144307813 10.1016/j.amjhyper.2004.05. 023 (Pubitemid 40029420)
23. Bakker E. N. T. P., van der Meulen E. T., van den Berg B. M., Everts V., Spaan J. A. E., Vanbavel E., Inward remodeling follows chronic vasoconstriction in isolated resistance arteries. Journal of Vascular Research 2002 39 1 12 20 2-s2.0-0036174654 10.1159/000048989 (Pubitemid 34158355)
24. Schiffrin E. L., Touyz R. M., From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. American Journal of Physiology 2004 287 2 H435 H446 2-s2.0-3242718855 10.1152/ajpheart.00262.2004 (Pubitemid 38960790)
25. Schiffrin E. L., Vascular stiffening and arterial compliance: implications for systolic blood pressure. American Journal of Hypertension 2004 17 12 S39 S48 2-s2.0-10644268692 10.1016/j.amjhyper.2004.08.019 (Pubitemid 39647570)
26. Wung B. S., Cheng J. J., Chao Y. J., Lin J., Shyy Y. J., Wang D. L., Cyclical strain increases monocyte chemotactic protein-1 secretion in human endothelial cells. American Journal of Physiology 1996 270 4 H1462 H1468 2-s2.0-0029978375
27. Schiffrin E. L., T Lynphocytes: a role in hypertension? Current Opinion in Nephrology and Hypertension 2010 19 181 186
28. Barzilay J. I., Peterson D., Cushman M., Heckbert S. R., Cao J. J., Blaum C., Tracy R. P., Klein R., Herrington D. M., The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. American Journal of Kidney Diseases 2004 44 1 25 34 2-s2.0-3042811123 10.1053/j.ajkd.2004.03.022 (Pubitemid 38880923)
29. Chae C. U., Lee R. T., Rifai N., Ridker P. M., Blood pressure and inflammation in apparently healthy men. Hypertension 2001 38 3 399 403 2-s2.0-0035571399 (Pubitemid 34225673)
30. Engström G., Gunnar.Engstrom@smi.mas.lu.se Janzon L., Berglund G., Lind P., Stavenow L., Hedblad B., Lindgärde F., Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 12 2054 2058 10.1161/01.ATV.0000041842.43905.F3 (Pubitemid 36025214)
31. Yudkin J. S., Stehouwer C. D. A., Emeis J. J., Coppack S. W., C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 4 972 978 2-s2.0-0032943709 (Pubitemid 29177345)
32. Ridker P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 1997 336 14 973 979 2-s2.0-0030956673 10.1056/NEJM199704033361401 (Pubitemid 27152782)
33. Ridker P. M., Buring J. E., Shih J., Matias M., Hennekens C. H., Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998 98 8 731 733 2-s2.0-0032566401 (Pubitemid 28391836)
34. Guzik T. J., Hoch N. E., Brown K. A., McCann L. A., Rahman A., Dikalov S., Goronzy J., Weyand C., Harrison D. G., Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. Journal of Experimental Medicine 2007 204 10 2449 2460 2-s2.0-34948825774 10.1084/jem.20070657 (Pubitemid 47529329)
35. Marvar P. J., Thabet S. R., Guzik T. J., Lob H. E., McCann L. A., Weyand C., Gordon F. J., Harrison D. G., Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circulation Research 2010 107 2 263 270 2-s2.0-77955171998 10.1161/CIRCRESAHA.110.217299
36. Lob H. E., Marvar P. J., Guzik T. J., Sharma S., McCann L. A., Weyand C., Gordon F. J., Harrison D. G., Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 2010 55 2 277 283 2-s2.0-74949095399 10.1161/HYPERTENSIONAHA.109.142646
37. Viel E. C., Lemarié C. A., Benkirane K., Paradis P., Schiffrin E. L., ernesto.schiffrin@mcgill.ca Immune regulation and vascular inflammation in genetic hypertension. American Journal of Physiology 2010 298 3 H938 H944 10.1152/ajpheart.00707.2009
38. Lassegue B., Clepmpus R. E., NAD(P)H oxidase: specific features, expression and regulation. American Journal of Physiology 2003 285 R277 R297
39. Touyz R. M., Schiffrin E. L., Reactive oxygen species in vascular biology: implications in hypertension. Histochemistry and Cell Biology 2004 122 4 339 352 2-s2.0-8644277006 10.1007/s00418-004-0696-7 (Pubitemid 39506592)
40. Touyz R. M., Yao G., Schiffrin E. L., c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 6 981 987 2-s2.0-0037783377 10.1161/01.ATV.0000069236.27911.68 (Pubitemid 36717143)
41. Fukui T., Ishizaka N., Rajagopalan S., Laursen J. B., Capers IV Q., Taylor W. R., Harrison D. G., De Leon H., Wilcox J. N., Griendling K. K., kgriend@emory.edu p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circulation Research 1997 80 1 45 51 (Pubitemid 27030367)
42. Griendling K. K., kgriend@emory.edu Sorescu D., Lassègue B., Ushio-Fukai M., Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 10 2175 2183
43. Touyz R. M., Chen X., Tabet F., Yao G., He G., Quinn M. T., Pagano P. J., Schiffrin E. L., Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circulation Research 2002 90 11 1205 1213 2-s2.0-0037076798 10.1161/01.RES.0000020404.01971.2F (Pubitemid 34786906)
44. Kalinina N., cardiocell@cardio.ru Agrotis A., Tararak E., Antropova Y., Kanellakis P., Ilyinskaya O., Quinn M. T., Smirnov V., Bobik A., Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 12 2037 2043 10.1161/01.ATV.0000040222.02255.0F (Pubitemid 36025211)
45. Touyz R. M., Schiffrin E. L., Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacological Reviews 2000 52 4 639 672 2-s2.0-0033635110
46. Rajagopalan S., Kurz S., Münzel T., Tarpey M., Freeman B. A., Griendling K. K., Harrison D. G., Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. Journal of Clinical Investigation 1996 97 8 1916 1923 2-s2.0-0030005713
47. Jung O., Marklund S. L., Geiger H., Pedrazzini T., Busse R., Brandes R. P., Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circulation Research 2003 93 7 622 629 2-s2.0-0141864392 10.1161/01.RES. 0000092140.81594.A8 (Pubitemid 37222158)
48. Touyz R. M., Tabet F., Schiffrin E. L., Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clinical and Experimental Pharmacology and Physiology 2003 30 11 860 866 2-s2.0-0344304669 10.1046/j.1440-1681.2003.03930.x (Pubitemid 37506154)
49. Schiffrin E. L., Touyz R. M., Inflammation and vascular hypertrophy induced by angiotensin II: role of NADPH oxidase-derived reactive oxygen species independently of blood pressure elevation? Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 5 707 709 2-s2.0-0038705115 10.1161/01.ATV.0000069907. 12357.7E (Pubitemid 36566155)
50. Sarkar S., Vellaichamy E., Young D., Sen S., Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. American Journal of Physiology 2004 287 1 H107 H117 2-s2.0-3042526284 10.1152/ajpheart.00763.2003 (Pubitemid 38802342)
51. Satoh C., Fukuda N., Hu W. Y., Nakayama M., Kishioka H., Kanmatsuse K., Role of endogenous angiotensin II in the increased expression of growth factors in vascular smooth muscle cells from spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology 2001 37 1 108 118 2-s2.0-0035177661 10.1097/00005344-200101000-00013 (Pubitemid 32012937)
52. Azhar M., Schultz J. E. J., Grupp I., Dorn G. W., Meneton P., Molin D. G. M., Gittenberger-de Groot A. C., Doetschman T., Transforming growth factor beta in cardiovascular development and function. Cytokine and Growth Factor Reviews 2003 14 5 391 407 2-s2.0-0042876796 10.1016/S1359-6101(03)00044-3 (Pubitemid 37099453)
53. Bobik A., Hypertension, transforming growth factor- β angiotensin II and kidney disease. Journal of Hypertension 2004 22 7 1265 1267 2-s2.0-3042754866 10.1097/01.hjh.0000125468.35523.7b (Pubitemid 38888070)
54. Shin G. T., Kim S. J., Ma K. A., Kim H. S., Kim D., ACE inhibitors attenuate expression of renal transforming growth factor- β 1 in humans. American Journal of Kidney Diseases 2000 36 5 894 902 2-s2.0-0033736454
55. Diep Q. N., Amiri F., Touyz R. M., Cohn J. S., Endemann D., Neves M. F., Schiffrin E. L., PPAR α activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002 40 6 866 871 2-s2.0-0036882119 10.1161/01.HYP.0000037969.41360.CC (Pubitemid 35434908)
56. Haffner S. M., Greenberg A. S., Weston W. M., Chen H., Williams K., Freed M. I., Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002 106 6 679 684 2-s2.0-0037031267 10.1161/01.CIR.0000025403.20953.23 (Pubitemid 34851926)
57. Tham D. M., Martin-McNulty B., Wang Y. X., Wilson D. W., Vergona R., Sullivan M. E., Dole W., Rutledge J. C., Angiotensin II is associated with activation of NF- κ B-mediated genes and downregulation of PPARs. Physiological Genomics 2003 11 21 30 2-s2.0-0037009883 (Pubitemid 37128718)
58. Qian C., Schoemaker R. G., van Gilst W. H., Roks A. J. M., The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function. Clinical Science 2009 116 4 301 314 2-s2.0-60549107875 10.1042/CS20080157
59. Imanishi T., Hano T., Nishio I., Angiotensin II accelarates endothelial progenitor cell senescence through induction of oxidative stress. Journal of Hypertension 2005 23 1 97 104 2-s2.0-12344256734 10.1097/00004872-200501000- 00018 (Pubitemid 40128986)
60. Yin T., Ma X., Zhao L., Cheng K., Wang H., Angiotensin II promotes NO production, inhibits apoptosis and enhances adhesion potential of bone marrow-derived endothelial progenitor cells. Cell Research 2008 18 7 792 799 2-s2.0-46749156708 10.1038/cr.2008.69 (Pubitemid 351948226)
61. Salguero G., Akin E., Templin C., Kotlarz D., Doerries C., Landmesser U., Grote K., Schieffer B., Renovascular hypertension by two-kidney one-clip enhances endothelial progenitor cell mobilization in a p47phox-dependent manner. Journal of Hypertension 2008 26 2 257 268 2-s2.0-38149097070 10.1097/HJH.0b013e3282f09f79
62. Kobayashi K., Imanishi T., Akasaka T., Endothelial progenitor cell differentiation and senescence in an angiotensin II-infusion rat model. Hypertension Research 2006 29 6 449 455 2-s2.0-33746315961 10.1291/hypres.29.449 (Pubitemid 44102813)
63. Imanishi T., Hano T., Nishio I., Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertension Research 2004 27 2 101 108 2-s2.0-1542411718 10.1291/hypres.27.101 (Pubitemid 38331920)
64. Kähler J., Ewert A., Weckmüller J., Stobbe S., Mittmann C., Köster R., Paul M., Meinertz T., Münzel T., muenzel@uke.uni-hamburg. de. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. Journal of Cardiovascular Pharmacology 2001 38 1 49 57 10.1097/00005344-200107000-00006 (Pubitemid 32634989)
65. Li L., Fink G. D., Watts S. W., Northcott C. A., Galligan J. J., Pagano P. J., Chen A. F., Endothelin-1 increases vascular superoxide via endothelinA-NADPH oxidase pathway in low-renin hypertension. Circulation 2003 107 7 1053 1058 2-s2.0-0037465438 10.1161/01.CIR.0000051459.74466.46 (Pubitemid 36258731)
66. Iglarz M., Touyz R. M., Amiri F., Lavoie M. F., Diep Q. N., Schiffrin E. L., Effect of peroxisome proliferator-activated receptor- α and-γ activators on vascular remodeling in endothelin-dependent hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 1 45 51 2-s2.0-0037231532 10.1161/01.ATV.0000047447.67827.CD (Pubitemid 36091624)
67. Amiri F., Virdis A., Fritsch Neves M., Iglarz M., Seidah N. G., Touyz R. M., Reudelhuber T. L., Schiffrin E. L., Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004 110 15 2233 2240 2-s2.0-5644247979 10.1161/01.CIR.0000144462. 08345.B9 (Pubitemid 39372507)
68. Muller D. N., Mervaala E. M. A., Schmidt F., Park J. K., Dechend R., Genersch E., Breu V., Löffler B. M., Ganten D., Schneider W., Haller H., Luft F. C., Effect of bosentan on nf- κ b, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000 36 2 282 290 2-s2.0-0033874297 (Pubitemid 30627001)
69. Touyz R. M., Yao G., Viel E., Amiri F., Schiffrin E. L., Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. Journal of Hypertension 2004 22 6 1141 1149 2-s2.0-2642551439 10.1097/00004872-200406000-00015 (Pubitemid 38721006)
70. Pu Q., Neves M. F., Virdis A., Touyz R. M., Schiffrin E. L., Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003 42 1 49 55 2-s2.0-0038141826 10.1161/01.HYP.0000078357.92682. EC (Pubitemid 36849598)
71. Vuurmans T. J. L., Boer P., Koomans H. A., Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension 2003 41 6 1253 1258 2-s2.0-0038796565 10.1161/01.HYP.0000072982.70666.E8 (Pubitemid 36706074)
72. McEniery C. M., Qasem A., Schmitt M., Avolio A. P., Cockcroft J. R., Wilkinson I. B., Endothelin-1 regulates arterial pulse wave velocity in vivo. Journal of the American College of Cardiology 2003 42 11 1975 1981 2-s2.0-0344010619 10.1016/j.jacc.2003.06.016 (Pubitemid 37485575)
73. Harada E., Yoshimura M., Yasue H., Nakagawa O., Nakagawa M., Harada M., Mizuno Y., Nakayama M., Shimasaki Y., Ito T., Nakamura S., Kuwahara K., Saito Y., Nakao K., Ogawa H., Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001 104 2 137 139 2-s2.0-0035838423 (Pubitemid 32655827)
74. Schiffrin E. L., Gutkowska J., Genest J., Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. American Journal of Physiology 1984 15 4 H608 H614 2-s2.0-0021341782 (Pubitemid 14148855)
75. Joffe H. V., Adler G. K., Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Failure Reviews 2005 10 1 31 37 2-s2.0-21244458789 10.1007/s10741-005-2346-0 (Pubitemid 40895314)
76. Blanco-Rivero J., Cachofeiro V., Lahera V., Aras-Lopez R., Márquez-Rodas I., Salaices M., Xavier F. E., Ferrer M., Balfagón G., Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 2005 46 1 107 112 2-s2.0-21744459701 10.1161/01.HYP.0000171479.36880.17 (Pubitemid 40946499)
77. Rocha R., Chander P. N., Khanna K., Zuckerman A., Stier C. T., Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998 31 1 451 458 2-s2.0-0031600240
78. Fiebeler A., Schmidt F., Müller D. N., Park J. K., Dechend R., Bieringer M., Shagdarsuren E., Breu V., Haller H., Luft F. C., Mineralocorticoid receptor affects AP-1 and nuclear factor- κ B activation in angiotensin II-induced cardiac injury. Hypertension 2001 37 2 787 793 2-s2.0-0035090207 (Pubitemid 32199067)
79. Ammarguellat F. Z., Gannon P. O., Amiri F., Schiffrin E. L., Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETa receptors. Hypertension 2002 39 2 679 684 2-s2.0-0036175568 10.1161/hy0202.103481 (Pubitemid 34165205)
80. Virdis A., Neves M. F., Amiri F., Viel E., Touyz R. M., Schiffrin E. L., Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002 40 4 504 510 2-s2.0-0036791717 10.1161/01.HYP. 0000034738.79310.06
81. Boulanger C. M., Microparticles, vascular function and hypertension. Current Opinion in Nephrology and Hypertension 2010 19 2 177 180 2-s2.0-76749103366 10.1097/MNH.0b013e32833640fd
82. Boulanger C. M., Amabile N., Tedgui A., Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006 48 2 180 186 2-s2.0-33748147424 10.1161/01.HYP.0000231507.00962.b5 (Pubitemid 44309805)
83. Preston R. A., Jy W., Jimenez J. J., Mauro L. M., Horstman L. L., Valle M., Aime G., Ahn Y. S., Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003 41 2 211 217 2-s2.0-0037315391 10.1161/01.HYP.0000049760.15764.2D (Pubitemid 36204891)
84. Koga H., Sugiyama S., Kugiyam K., Elevated levels of VE-cadherin-positive endothelial mircoparticles in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology 2005 45 1622 1630 (Pubitemid 40704497)
85. Esposito K., Ciotola M., Giugliano F., Schisano B., Improta L., Improta M. R., Beneduce F., Rispoli M., De Sio M., Giugliano D., Endothelial microparticles correlate with erectile dysfunction in diabetic men. International Journal of Impotence Research 2007 19 2 161 166 2-s2.0-33847398304 10.1038/sj.ijir.3901500 (Pubitemid 46340832)
86. Bernal-Mizrachi L., Jy W., Jimenez J. J., Pastor J., Mauro L. M., Horstman L. L., De Marchena E., Ahn Y. S., High levels of circulating endothelial microparticles in patients with acute coronary syndromes. American Heart Journal 2003 145 6 962 970 2-s2.0-0038620493 10.1016/S0002-8703(03)00103-0 (Pubitemid 36688245)
87. Chironi G. N., Boulanger C. M., Simon A., Dignat-George F., Freyssinet J. M., Tedgui A., Endothelial microparticles in diseases. Cell and Tissue Research 2009 335 1 143 151 2-s2.0-57749208172 10.1007/s00441-008-0710-9
88. Wang J. M., Wang Y., Huang J. Y., Yang Z., Chen L., Wang L. C., Tang A. L., Lou Z. F., Tao J., C-reactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation. Journal of Vascular Research 2007 44 3 241 248 2-s2.0-34247092528 10.1159/000100558 (Pubitemid 46597306)
89. Boulanger C. M., Amabile N., Guérin A. P., Pannier B., Leroyer A. S., Nguyen C., Mallat Z., Tedgui A., London G. M., In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension 2007 49 4 902 908 2-s2.0-34047237415 10.1161/01.HYP. 0000259667.22309.df (Pubitemid 351664206)
90. Amabile N., Guérin A. P., Leroyer A., Mallat Z., Nguyen C., Boddaert J., London G. M., Tedgui A., Boulanger C. M., Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. Journal of the American Society of Nephrology 2005 16 11 3381 3388 2-s2.0-33644876174 10.1681/ASN.2005050535 (Pubitemid 46179341)
91. Brodsky S. V., Zhang F., Nasjletti A., Goligorsky M. S., Endothelium-derived microparticles impair endothelial function in vitro. American Journal of Physiology 2004 286 5 H1910 H1915 2-s2.0-1942533438 10.1152/ajpheart.01172.2003 (Pubitemid 38525481)
92. Mause S. F., von Hundelshausen P., Zernecke A., Koenen R. R., Weber C., cweber@ukaachen.de Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 7 1512 1518 10.1161/01.ATV.0000170133. 43608.37 (Pubitemid 40923377)
93. Nomura S., shosaku-n@mbp.ocn.ne.jp Shouzu A., Omoto S., Nishikawa M., Fukuhara S., Iwasaka T., Losartan and simvastatin inhibit platelet activation in hypertensive patients. Journal of Thrombosis and Thrombolysis 2005 18 3 177 185 10.1007/s11239-005-0343-8 (Pubitemid 40552932)
94. Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S., Iwasaka T., Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thrombosis Research 2006 117 4 385 392 2-s2.0-32044449604 10.1016/j.thromres.2005.04.008 (Pubitemid 43197489)
95. Nomura S., Shouzu A., Omoto S., Nishikawa M., Iwasaka T., Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clinical and Applied Thrombosis/Hemostasis 2004 10 2 133 141 2-s2.0-1842852181 10.1177/ 107602960401000203 (Pubitemid 38490081)
96. Labiós M., Martinez M., martinezmar@gva.es Gabriel F., Guiral V., Muñoz A., Aznar J., Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. American Journal of Hypertension 2004 17 9 757 763 10.1016/j.amjhyper.2004.05. 010 (Pubitemid 39201089)